Aljosja Rogiers
Overview
Explore the profile of Aljosja Rogiers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rogiers A, Dimitriou F, Lobon I, Harvey C, Vergara I, Pires da Silva I, et al.
Eur J Cancer
. 2024 Jan;
198:113506.
PMID: 38184928
Background: Immune checkpoint inhibitors are frequently associated with the development of immunotherapy-related adverse events (irAEs). The exact etiology, including the role of environmental factors, remains incompletely understood. Methods: We analyzed...
2.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Wu M, Shepherd S, Fendler A, Carr E, Au L, Harvey R, et al.
Cancer Cell
. 2023 Apr;
41(5):821-823.
PMID: 37116490
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
3.
Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):92.
PMID: 37072838
Background: One of the key limitations of targeted cancer therapies is the rapid onset of therapy resistance. Taking BRAF-mutant melanoma as paradigm, we previously identified the lipogenic regulator SREBP-1 as...
4.
Spain L, Coulton A, Lobon I, Rowan A, Schnidrig D, Shepherd S, et al.
Cancer Discov
. 2023 Mar;
13(6):1364-1385.
PMID: 36977461
Significance: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many...
5.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Wilkinson K, et al.
Cell Rep Med
. 2022 Oct;
3(10):100781.
PMID: 36240755
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the...
6.
Wessels T, Rogiers A, Schoffski P
Oncol Res Treat
. 2022 Jul;
45(10):618-621.
PMID: 35882208
Introduction: Patients with metastatic soft-tissue sarcoma generally have a poor prognosis. Although chemotherapy is associated with improved overall survival in these patients, long-term benefit is rare. Case Report: We report...
7.
Holmberg C, Ny L, Hieken T, Block M, Carr M, Sondak V, et al.
Eur J Cancer
. 2022 Jun;
169:210-222.
PMID: 35644725
Purpose: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials...
8.
Rogiers A, Lobon I, Spain L, Turajlic S
Cancer Res
. 2022 Apr;
82(10):1849-1857.
PMID: 35476646
Cancer is an evolutionary process that is characterized by the emergence of multiple genetically distinct populations or clones within the primary tumor. Intratumor heterogeneity provides a substrate for the selection...
9.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Schmitt A, et al.
Cancer Cell
. 2022 Apr;
40(4):438.
PMID: 35413273
No abstract available.
10.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2022 Feb;
2(12):1305-1320.
PMID: 35121899
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated...